Clean Science HALS mix improvement and partnerships support medium-term growth

Investment View and Valuation

Prabhudas Lilladher retains its HOLD rating on Clean Science and Technology and reduces the target price to Rs 745 from Rs 804. The broker remains cautious because of the uncertain macroeconomic environment, continued realisation pressure in certain legacy products and the delay in Performance Chemicals-II.

Forthcoming capacity additions, the ramp-up in HALS and strategic partnerships could support medium-term growth. The target price is based on 22 times FY28E EPS. At the report's CMP, the stock trades at 22 times FY28E EPS.

Q1FY27 Financial Performance

Clean Science reported consolidated Q1FY27 revenue of Rs 2,684 million, increasing 10.5 per cent year on year and 7.7 per cent quarter on quarter. Revenue was 9.5 per cent above Prabhudas Lilladher's estimate of Rs 2,451 million and ahead of consensus at Rs 2,600 million, driven by higher realisations and a larger HALS contribution.

Q1FY27 EBITDA was Rs 964 million, down 3.4 per cent year on year but 0.7 per cent higher sequentially. EBITDA was 19.8 per cent above the broker's estimate of Rs 805 million and above consensus of Rs 877 million. EBITDA margin contracted 520 basis points year on year and 250 basis points quarter on quarter to 35.9 per cent, as gross margin fell to 60.9 per cent from 65.5 per cent in Q1FY26 and 63.5 per cent in Q4FY26 amid higher raw-material costs.

Reported PAT was Rs 734 million, up 4.7 per cent year on year and 25.9 per cent quarter on quarter, principally aided by higher other income. PAT margin was 27 per cent.

HALS Growth and Product Mix

Management said HALS volumes were about 1,000 tonnes in Q1FY27. The mix shifted towards higher-grade HALS, with blended realisation increasing to about Rs 550 per kg from about Rs 440 per kg. Exports accounted for 50 per cent of HALS sales, and management has guided for HALS revenue of Rs 2.5 billion to Rs 3.0 billion in FY27.

The overall domestic-to-export mix was 65 per cent to 35 per cent. Product concentration has also reduced, with the top products contributing 60 per cent of Q1FY27 revenue versus 85 per cent in Q1FY23.

Capacity Additions and Strategic Partnerships

Management expects the Hydroquinone and Catechol plants to ramp up, with commercial supplies beginning in August-September 2026. Commercial production under the Geneus collaboration is expected from Q3FY27. Clean Science will manufacture using Geneus technology, and the product will be co-branded.

Management expects cumulative Geneus-project revenue of Rs 3.0 billion to Rs 3.5 billion over four years, with capex of about Rs 250 million. Clean Science has also signed a five-year strategic supply agreement with Kemin Industries, which will require new capacity. Related capex has not yet been announced.

Commercialisation of Performance Chemicals-II has been deferred to November 2026 because of manpower shortages.

Broker Estimates

The broker expects FY28E EBITDA margin of 36 per cent, PAT margin of 24.4 per cent, exports to account for 60 per cent of revenue, and return on equity and return on capital employed of 16.6 per cent and 19.9 per cent, respectively.

Relative to prior estimates, FY27E and FY28E sales estimates rise 0.4 per cent and 2.1 per cent, respectively, while EBITDA estimates decline 1.8 per cent and 0.4 per cent, respectively.

Key Factors to Monitor

• Uncertain macroeconomic conditions and realisation pressure in certain legacy products remain key concerns.
• The ramp-up of HALS, Hydroquinone and Catechol capacity could support growth.
• The Geneus collaboration and Kemin Industries supply agreement provide potential medium-term opportunities, subject to execution and capacity additions.
• The delayed Performance Chemicals-II commercialisation and associated manpower shortages remain execution risks.